Our purpose is to provide the results of a prospective study evaluating prostate-specific membrane antigen-targeted 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) PET/CT in patients with biochemical failure after radical prostatectomy for prostate cancer (PCa). Methods: Thirty-one patients with postprostatectomy serum prostate-specific antigen (PSA) levels of at least 0.2 ng/mL and negative conventional imaging results were enrolled in this study and imaged with 18F-DCFPyL PET/CT. A consensus central review identified foci of radiotracer uptake consistent with sites of PCa. Descriptive statistics were used. Results: Twenty-one patients (67.7%) had at least 1 finding on 18F-DCFPyL PET/CT consistent with a site of PCa. Imaging was positive in 59.1% of patients with a PSA level of less than 1.0 ng/mL and in 88.9% of patients with a PSA level of more than 1.0 ng/mL. The median SUVmax across all lesions was 11.6 (range, 1.5-57.6). Conclusion: In this prospective study using the prostate-specific membrane antigen-targeted PET agent 18F-DCFPyL, most patients with biochemical failure after radical prostatectomy had foci of suggestive uptake, even at low serum PSA levels.

中文翻译：

---

前列腺癌根治性前列腺切除术后生化失败男性 PSMA 靶向 18F-DCFPyL PET/CT 的前瞻性评估。

我们的目的是提供一项前瞻性研究的结果，该研究评估前列腺特异性膜抗原靶向 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-氨基]-戊基}-脲基)-戊二酸) PET/CT 用于前列腺癌 (PCa) 根治性前列腺切除术后生化失败的患者。方法：31 例前列腺切除术后血清前列腺特异性抗原 (PSA) 水平至少为 0.2 ng/mL 且常规成像结果为阴性的患者被纳入本研究，并使用 18F-DCFPyL PET/CT 进行成像。一项共识中央审查确定了与 PCa 部位一致的放射性示踪剂摄取病灶。使用了描述性统计。结果：21 名患者 (67.7%) 在 18F-DCFPyL PET/CT 上至少有 1 个发现与 PCa 部位一致。59 例影像学阳性。PSA 水平低于 1.0 ng/mL 的患者占 1%，PSA 水平高于 1.0 ng/mL 的患者占 88.9%。所有病变的中位 SUVmax 为 11.6（范围，1.5-57.6）。结论：在这项使用前列腺特异性膜抗原靶向 PET 试剂 18F-DCFPyL 的前瞻性研究中，大多数根治性前列腺切除术后生化失败的患者即使在血清 PSA 水平较低时也有提示摄取的病灶。